Is TKPHF.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

205 people get TKPHF.PK articles and Market Currents by email alert.

Get email alerts on TKPHF.PK »

HEADLINES:

Takeda Pharmaceutical's Management Discusses F4Q2013 Results - Earnings Call Transcript
Thu, May 9
Is It The End Of The Road For Affymax?
Efsinvestment • Thu, Mar 28 • 16 Comments
Affymax Will Rise Again
WalkTheTalk • Wed, Mar 20 • 90 Comments
Today's NPS Deal- Putting Drugs In The Right Hands
Bryce Istvan • Tue, Mar 19
Is Affymax A Knife Worth Catching?
Brian L. Wilson • Sun, Mar 10 • 12 Comments
Is Takeda Interested In Aastrom Bio?
PropThink • Wed, Feb 27 • 20 Comments
Multiple Myeloma And Different Treatment Approaches
Carl Cachia • Sun, Feb 17 • 9 Comments
Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma

Business Wire (Dec 9, 2012)
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas

Business Wire (Dec 9, 2012)
Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study

Business Wire (Dec 9, 2012)
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
LifeSci Advisors • Thu, Nov 29, 2012 • 3 Comments
Cashed Up Biotech Vanda Could Keep On Falling
Praveen Jayarajan • Wed, Sep 5, 2012 • 7 Comments
Lexicon Needs Differentiated Data To Drive Deals And Value
Stephen Simpson • Mon, Aug 6, 2012 • 11 Comments
Dendreon: Who's That Knocking On Their Door?
Theodore Cohen • Sun, Jul 29, 2012 • 48 Comments
Closer Look: Furiex's Big Bounce
Brian L. Wilson • Wed, Jul 11, 2012
Affymax Is The Perfect Takeover Candidate
Paulo Santos • Wed, Jun 13, 2012 • 10 Comments
6 Best Biotech Stocks With More Upside Potential
StockPandit • Mon, May 7, 2012 • 4 Comments
Will Amylin Stand To Gain From A Citizen's Petition Challenging Victoza?
Stephen Simpson • Fri, Apr 20, 2012 • 5 Comments
Affymax's Anemia Drug Will Create Added Competition For Amgen
The Burrill Report • Sun, Apr 1, 2012 • 5 Comments
Furiex Pharmaceutical's Coming Events Could Boost Stock Price
Roy Manning III • Mon, Mar 26, 2012 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Is Takeda Interested In Aastrom Bio?
PropThink • Wed, Feb 27 • 20 Comments
Takeda Pharma Ups Commitment to China
ChinaBio Today • Thu, Mar 24, 2011
Hope Dies Out for Takeda's Cholesterol Medication
Derek Lowe • Mon, Apr 7, 2008

Is It The End Of The Road For Affymax?
Efsinvestment • Thu, Mar 28 • 16 Comments
Affymax Will Rise Again
WalkTheTalk • Wed, Mar 20 • 90 Comments
Today's NPS Deal- Putting Drugs In The Right Hands
Bryce Istvan • Tue, Mar 19
Is Affymax A Knife Worth Catching?
Brian L. Wilson • Sun, Mar 10 • 12 Comments
Multiple Myeloma And Different Treatment Approaches
Carl Cachia • Sun, Feb 17 • 9 Comments
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
LifeSci Advisors • Thu, Nov 29, 2012 • 3 Comments
Cashed Up Biotech Vanda Could Keep On Falling
Praveen Jayarajan • Wed, Sep 5, 2012 • 7 Comments
Lexicon Needs Differentiated Data To Drive Deals And Value
Stephen Simpson • Mon, Aug 6, 2012 • 11 Comments
Dendreon: Who's That Knocking On Their Door?
Theodore Cohen • Sun, Jul 29, 2012 • 48 Comments
Closer Look: Furiex's Big Bounce
Brian L. Wilson • Wed, Jul 11, 2012
Affymax Is The Perfect Takeover Candidate
Paulo Santos • Wed, Jun 13, 2012 • 10 Comments
6 Best Biotech Stocks With More Upside Potential
StockPandit • Mon, May 7, 2012 • 4 Comments
Will Amylin Stand To Gain From A Citizen's Petition Challenging Victoza?
Stephen Simpson • Fri, Apr 20, 2012 • 5 Comments
Affymax's Anemia Drug Will Create Added Competition For Amgen
The Burrill Report • Sun, Apr 1, 2012 • 5 Comments
Furiex Pharmaceutical's Coming Events Could Boost Stock Price
Roy Manning III • Mon, Mar 26, 2012 • 4 Comments
Diabetes Market: Eli Lilly's Classic Pharma Vs. Sanofi Aventis' Modern Synergy
Jessica King Holden • Thu, Mar 8, 2012 • 4 Comments
IPO Preview: ChemoCentryx
IPOdesktop • Tue, Feb 7, 2012
AstraZeneca Axes 7,300 Jobs, 12% Of Workforce
The Burrill Report • Sun, Feb 5, 2012 • 1 Comment
Best Selling Drugs Going Off Patent In 2012
Jon Crowley • Thu, Jan 5, 2012 • 6 Comments
Kubota Buys Kverneland On The Cheap
Clemens Scholl • Mon, Dec 19, 2011 • 7 Comments

Takeda Pharmaceutical's Management Discusses F4Q2013 Results - Earnings Call Transcript
Thu, May 9

Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma

Business Wire (Dec 9, 2012)
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas

Business Wire (Dec 9, 2012)
Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study

Business Wire (Dec 9, 2012)

TKPHF.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for TKPHF.PK.

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, April 23, 8:07 AM Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket. 1 Comment [Healthcare, On the Move]
Wednesday, April 3, 11:42 AM Sucampo Pharmaceuticals (SCMP +6.6%) climbs higher after Cantor Fitzgerald says excitement surrounding the opioid-induced constipation drug Amitiza "could significantly rally the stock" in the short-term. Additionally, the company's partnership with Takeda (TKPHF.PK +3.4%) makes for a compelling long-term story. SCMP is initiated at Buy with a $9 price target. Comment! [Healthcare]
Tuesday, March 19, 8:18 AM NPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR) Comment! [Healthcare, M&A]
Sunday, February 24, 3:31 AM Affymax (AFFY) and Japan's Takeda Pharmaceutical (TKPHF.PK) have voluntarily recalled all lots of anemia treatment Omontys in the U.S. following reports of "serious hypersensitivity reactions," including fatalities in "0.02%" of over 25,000 patients after an initial injection. The recall comes after Fresenius said earlier this month that it was halting a pilot program using Omontys. (PR) 1 Comment [Healthcare]
Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
Friday, June 22, 2012, 9:03 AM NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK) say a European panel recommended their Revestive drug receive marketing approval as a once-daily treatment for adults with short bowel syndrome. Comment! [Healthcare, On the Move]
Thursday, December 1, 2011, 7:33 PM Japanese stocks open slightly higher after a relatively flat trading day Wall Street overnight. The Nikkei Average is up 0.22% with telecom and pharmaceutical shares among the gainers: Daiichi Sankyo (DSKYF.PK +1.9%), Takeda Pharmaceutical (TKPHF.PK +1.9%), Softbank (SFTBY.PK +1.9%) and Nippon Telegraph & Telephone (NTT +2.2%). 1 Comment [Global & FX]
Thursday, May 19, 2011, 5:54 AM Takeda Pharmaceutical (TKPHF.PK) agrees to buy closely-held Swiss rival Nycomed for €9.6B ($13.7B) in a move that will extend Takeda's reach into emerging markets. The price tag, which is slightly larger than had been expected, includes €3.6B of net debt. Comment! [Healthcare, M&A]
Wednesday, May 18, 2011, 5:05 AM Takeda Pharmaceutical (TKPHF.PK), Asia's top drug maker, is reportedly set to announce the purchase of closely-held Swiss rival Nycomed as soon as this morning. The price tag is expected to be around ¥1T ($12B). (previously) Comment! [Healthcare, M&A]
Thursday, May 12, 2011, 4:30 AM Takeda Pharmaceutical (TKPHF.PK), Asia's top drug maker, is reportedly in talks to buy closely-held Swiss rival Nycomed. Sources say Takeda and Nycomed have discussed an offer above €8B ($11.4B) but that Nycomed may hold out for more than €10B. Comment! [Healthcare, M&A]
Thursday, February 24, 2011, 3:56 PM Last year, SSBT OD05 Omnibus Account Treaty Clients appeared as a top 10 shareholder in several major Japanese companies. Behind SSBT? China, which has stealthily built stakes in firms like Mitsubishi Financial, Canon, Sony, and Tokyo Electric, among others. Comment! [Global & FX]
Wednesday, December 8, 2010, 7:27 AM Orexigen (OREX) is +152% premarket after an FDA advisory panel voted 13-7 to recommend the approval of diet drug Contrave. The decision came as a surprise, as the FDA has set a very high bar for diet drugs and already rejected several other obesity treatments this year. Rivals gaining on the news: VVUS +12.8%, ARNA +9.9%. Comment!
Monday, November 15, 2010, 9:12 AM Genzyme (GENZ) +0.8% premarket, apparently on chatter about a possible acquisition by Takeda Pharmaceutical (TKPHF.PK), Japan's top drug maker. Takeda could pay $82/share for the company, far surpassing Sanofi's (SNY) $69/share hostile bid. Comment!
Tuesday, November 2, 2010, 8:52 AM Commonly used diabetes drugs such as metformin may help prevent and control lung cancer, research shows, and metformin, available in cheaper generic form, had a more powerful effect than newer TZD drugs such as those by GlaxoSmithKline (GSK) and Takeda (TKPHF.PK). Comment!
Thursday, September 2, 2010, 8:04 AM Orexigen Therapeutics (OREX) enters into a partnership with Takeda (TKPHF.PK) to commercialize Contrave, an obesity drug, in North America. OREX +22.2% premarket. (PR) 1 Comment

TKPHF.PK Takeda Pharmaceutica

TKPHF.PK

Takeda Pharmaceutica